A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects with Relapsed or Refractory Solid Tumors Associated with EphA2 Expression (MedImmune MI-CP177).

Trial Profile

A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects with Relapsed or Refractory Solid Tumors Associated with EphA2 Expression (MedImmune MI-CP177).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2011

At a glance

  • Drugs MEDI 547 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Actual initiation date changed from Jun 2009 to Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top